- Home
- MLCO vs PTGX Comparison
MLCO vs PTGX Comparison
Compare MLCO & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLCO
- PTGX
- Stock Information
- Founded
- MLCO 2004
- PTGX 2006
- Country
- MLCO Hong Kong
- PTGX United States
- Employees
- MLCO N/A
- PTGX N/A
- Industry
- MLCO Hotels/Resorts
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- MLCO Consumer Discretionary
- PTGX Health Care
- Exchange
- MLCO Nasdaq
- PTGX Nasdaq
- Market Cap
- MLCO 3.2B
- PTGX 5.0B
- IPO Year
- MLCO 2006
- PTGX 2016
- Fundamental
- Price
- MLCO $8.51
- PTGX $79.54
- Analyst Decision
- MLCO Buy
- PTGX Strong Buy
- Analyst Count
- MLCO 6
- PTGX 9
- Target Price
- MLCO $9.78
- PTGX $86.22
- AVG Volume (30 Days)
- MLCO 2.6M
- PTGX 1.3M
- Earning Date
- MLCO 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- MLCO N/A
- PTGX N/A
- EPS Growth
- MLCO N/A
- PTGX N/A
- EPS
- MLCO 0.26
- PTGX 0.72
- Revenue
- MLCO $5,061,044,000.00
- PTGX $209,217,000.00
- Revenue This Year
- MLCO $12.67
- PTGX N/A
- Revenue Next Year
- MLCO $3.25
- PTGX $140.23
- P/E Ratio
- MLCO $33.18
- PTGX $110.44
- Revenue Growth
- MLCO 11.46
- PTGX N/A
- 52 Week Low
- MLCO $4.55
- PTGX $33.31
- 52 Week High
- MLCO $10.15
- PTGX $93.25
- Technical
- Relative Strength Index (RSI)
- MLCO 52.63
- PTGX 62.21
- Support Level
- MLCO $8.00
- PTGX $75.44
- Resistance Level
- MLCO $8.73
- PTGX $80.43
- Average True Range (ATR)
- MLCO 0.34
- PTGX 2.61
- MACD
- MLCO 0.07
- PTGX -0.23
- Stochastic Oscillator
- MLCO 75.54
- PTGX 89.38
About MLCO Melco Resorts & Entertainment Limited
Melco Resorts & Entertainment is one of only six licensed casino operators in Macao. It operates Altira, a complex focused on premium customers; City of Dreams, an integrated resort in Cotai serving both mass-market and premium patrons; and Mocha Clubs' electronic gaming machines. The company also has a majority interest in Studio City, which opened in 2015. Outside Macao, Melco owns City of Dreams Manila in the Philippines and City of Dreams Mediterranean in Cyprus. The business mix in terms of adjusted EBITDA was about 81% from Macao, with the rest largely from the Philippines as of 2024.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.